m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04090)
Name
CEQ-508
Synonyms
CEQ-501; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Cequent; TkRNAis (oral, familial adenomatous polyposis/colon cancer), Marina
    Click to Show/Hide
Status
Phase 1/2
TTD Drug ID
D00GBZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Beta-catenin (CTNNB1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [2], [3]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [2], [4]
RNA binding protein X (RBMX)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The RNA binding protein X (RBMX) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [2], [5]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [2], [4]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Beta-catenin (CTNNB1) is a therapeutic target for CEQ-508. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of CEQ-508 through regulating the expression of Beta-catenin (CTNNB1). [2], [6]
References
Ref 1 FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (CSCC) by targeting Beta-catenin through mRNA demethylation. Mol Carcinog. 2018 May;57(5):590-597. doi: 10.1002/mc.22782. Epub 2018 Feb 1.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nat Commun. 2022 May 13;13(1):2672. doi: 10.1038/s41467-022-30217-7.
Ref 4 Ethionine-mediated reduction of S-adenosylmethionine is responsible for the neural tube defects in the developing mouse embryo-mediated m6A modification and is involved in neural tube defects via modulating Wnt/Beta-catenin signaling pathway. Epigenetics Chromatin. 2021 Dec 4;14(1):52. doi: 10.1186/s13072-021-00426-3.
Ref 5 N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063. doi: 10.1093/nar/gkx141.
Ref 6 Loading MicroRNA-376c in Extracellular Vesicles Inhibits Properties of Non-Small Cell Lung Cancer Cells by Targeting YTHDF1. Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820977525. doi: 10.1177/1533033820977525.